Last reviewed · How we verify
Leuprolide, Degarelix or Relugolix
Leuprolide, Degarelix or Relugolix is a Small molecule drug developed by NYU Langone Health. It is currently in Phase 2 development.
At a glance
| Generic name | Leuprolide, Degarelix or Relugolix |
|---|---|
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (PHASE2)
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT (PHASE2)
- Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging (PHASE3)
- ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer (PHASE2)
- Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (PHASE2)
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (PHASE3)
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (PHASE3)
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Leuprolide, Degarelix or Relugolix CI brief — competitive landscape report
- Leuprolide, Degarelix or Relugolix updates RSS · CI watch RSS
- NYU Langone Health portfolio CI
Frequently asked questions about Leuprolide, Degarelix or Relugolix
What is Leuprolide, Degarelix or Relugolix?
Leuprolide, Degarelix or Relugolix is a Small molecule drug developed by NYU Langone Health.
Who makes Leuprolide, Degarelix or Relugolix?
Leuprolide, Degarelix or Relugolix is developed by NYU Langone Health (see full NYU Langone Health pipeline at /company/nyu-langone-health).
What development phase is Leuprolide, Degarelix or Relugolix in?
Leuprolide, Degarelix or Relugolix is in Phase 2.
Related
- Manufacturer: NYU Langone Health — full pipeline